AstraZeneca’s post-heart attack drug gets NICE recommendation
pharmafile | November 4, 2016 | News story | Medical Communications, Sales and Marketing | AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention treatment for aetherothrombotic events in high-risk patients who have previously suffered myocardial infarction.
The drug has been approved for treatment as a 60mg dose in combination with aspirin. Patients in England and Wales with a history of heart attacks of at least one year and a high risk of another event may now continue treatment with the new indication to a maximum of three years.
The drug is already approved by NICE and the Scottish Medicines Consortium (SMC) as a 90mg dose in the same combination for patients with acute coronary syndrome (ACS) for up to 12 months only. Treatment with the new indication can now be started as a continuation therapy after the initial one-year treatment of the 90mg dose.
“Secondary prevention for heart attack patients is critically important for their physical and psychological wellbeing,” commented Professor Rob Storey, professor of Cardiology, University of Sheffield. “Today’s NICE recommendation is an important step forward in enabling us as clinicians to continue reducing patients’ risk of a further atherothrombotic event, including another heart attack or stroke, in the first few years following an initial heart attack.”
Lisa Anson, country president of AstraZeneca UK and Ireland, added:
“We welcome this very important and positive recommendation by NICE. With more people than ever surviving heart attacks, it is critical to recognise the need to provide ongoing management of the underlying condition in the immediate years following an attack for the prevention of further events. At AstraZeneca we are committed to helping appropriate NHS patients who could benefit from ticagrelor 60mg get access to the treatment.”
Matt Fellows
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
